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Nicholas Deutsch, MD, Charles B. Hantler, MD, Fred Morady, MD, and Marvin Kirsh, MD 
I T HAS BEEN ESTIMATED that 400,000 people die annually from sudden cardiac 
arrest in the United States.’ Various treatment 
modalities have been tried in patients at high risk 
for sudden death from ventricular fibrillation, 
but delivery of an electrical countershock of 
sufficient energy remains the only reliable 
treatment.* The automatic internal cardioverter- 
defibrillator (AICD) has dramatically changed 
the treatment of patients at high risk for sudden 
death. The first clinical trial was by Mirowski et 
al3 in 1980. The implantation of AICDs has 
greatly increased since the Food and Drug Ad- 
ministration approved the device in 1985. There 
have been more than 3,000 AICDs inserted since 
1982, at greater than 200 centerse4 
The results of conventional treatment are 
not optimal. The l-year sudden-cardiac-death 
rate for survivors of an episode of cardiac arrest 
receiving empiric drug therapy is 20% to 50%.5-9 
The l-year sudden-cardiac-death rate for pa- 
tients with electrophysiologic or Holter-monitor- 
guided therapy is 2% to 1 5%.5,6Y9 The results from 
a number of series of patients with AICDs, 
however, have been very encouraging. The l- 
year sudden-cardiac-death rate of AICD pa- 
tients has been reported to be about 2%.‘@14 
DEVICE 
The AICD device contains lithium batter- 
ies, capacitors, a piezoelectric crystal, and connec- 
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tors for the different electrodes. The internal 
circuitry is attached to the receptacles for the 
electrode leads by hermetically sealed feed- 
throughs, which protect the device from electro- 
magnetic interference. There are two defibril- 
lating electrodes made of silicone rubber and 
titanium. The first defibrillating electrode is 
either an intravascular spring electrode or, alter- 
natively, a patch electrode. The intravascular 
spring electrode is placed by percutaneous cannu- 
lation of the subclavian vein into the superior 
vena cava near the right atrium. Alternatively, a 
patch electrode may be placed over the right 
atrium or ventricle. The other end of the first 
electrode is tunneled subcutaneously to the left 
upper quadrant of the abdomen. The second 
defibrillating electrode is a wire-mesh patch sewn 
to the cardiac apex. A separate electrode system 
is used for rate sensing. The rate-sensing elec- 
trode is either a transvenous lead placed in the 
right ventricular apex, or a bipolar epicardial 
screw-on pair placed on normal myocardium.15 
(See Figs 1 and 2). 
The AICD typically requires 5 to 20 sec- 
onds to sense ventricular tachycardia or fibrilla- 
tion. It then takes 5 to 15 seconds to charge its 
energy-storage capacitors. The first shock deliv- 
ered is usually 23 to 28 J. After appropriate 
sensing and charging periods of 10 to 35 seconds, 
the device will deliver second, third, and fourth 
shocks, if necessary. The device will not deliver 
more than four consecutive shocks because 
this prevents multiple shocks in misdiagnosed 
rhythms.i5 
There are two general types of AICDs. One 
is triggered to deliver a countershock when a 
heart rate algorithm alone is satisfied, and the 
other is triggered when both a heart rate and a 
probability density function (PDF) algorithm 
are met. The heart rate algorithm is based on the 
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Fig 1. The electrode configuration with two trans- 
venously placed electrodes. the rate-sensing, bipolar elec- 
trode, and the defibrillating. spring electrode, along with a 
single epicardial defibrillating patch electrode. RV, right 
ventricle; WC, superior vena cava; RA. right atrium. 
amount of time an average heart rate spends 
above a preset value, specified by the physician at 
the time of manufacture. Using only the heart 
rate algorithm, the device cannot differentiate 
among sinus, supraventricular, and ventricular 
tachycardias. The PDF analyzes the amount of 
time the QRS complex spends away from the 
isoelectric baseline as sensed by the two defibril- 
lating electrodes. During sinus rhythm or rela- 
tively slow supraventricular tachycardia without 
Fig 2. The electrode configuration with all three 
placed epicardially. The two defibrillating, patch electrodes 
and the screw-in, rate-sensing electrode are shown. 
aberration, the electrocardiographic (ECG) wave- 
form spends most of its time on the isoelectric 
baseline. Conversely, during ventricular tachycar- 
dia or coarse ventricular fibrillation, the ECG 
waveform deviates from the isoelectric baseline a 
high percentage of the time and satisfies the 
PDF.‘4915 The advantage of using a heart rate 
trigger alone is that a relatively narrow complex 
ventricular tachycardia, which might not meet 
the PDF, will be countershocked. In addition, a 
shock is delivered more rapidly when sensing is 
based on rate only. 
The AICD device has three different modes. 
They are the active, inactive, and electrophysio- 
logic test modes. Application of a magnet to the 
AICD for less than 30 seconds will generate a 
signal that conveys its mode and for more than 30 
seconds will change its mode. When a magnet is 
initially applied to the inactivated AICD, the 
piezoelectric crystals transmit a constant shrill 
tone, signifying that the device is deactivated. 
After 30 seconds, pulsed tones synchronous with 
the ECG R wave are then emitted. The AICD is 
now in the electrophysiology test mode, which 
enables the device to sense a dysrhythmia with- 
out discharging. Upon removal of the magnet, 
the device is activated. Conversely, when a mag- 
net is first applied to the activated device, pulsed 
tones synchronous with the R wave of the ECG 
are transmitted, denoting that the device is in the 
active mode. Thirty seconds later, a continuous 
shrill is audible, indicating that the device has 
switched to the inactive mode.17 
INDICATIONS AND CONTRAINDICATIONS 
Criteria for implantation have been liberal- 
ized since the AICD was first introduced clini- 
cally, and will continue to evolve as more clinical 
data are obtained. Table 1 lists common in- 
dications and contraindications for AICD 
insertion. 12,15,16,18-21 
PREOPERATIVE CONSIDERATIONS 
Candidates for AICD implantation need a 
thorough preoperative evaluation. This evalua- 
tion typically includes cardiac catheterization, 
including coronary arteriography and left ventric- 
ulography, so that decisions about the need for 
coronary or valvular surgery can be made. These 
patients will have undergone thorough electro- 
physiologic testing to determine the inducibility 
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Table 1. Indications and Contraindications for AICD 
Insertion 
Indications 
History of sudden cardiac arrest not associated with 
acute myocardial infarction 
and 
- ‘Dysrhythmia that cannot be induced by electro- 
physiologic testing 
Or 
- Pharmacologic failure as assessed by electro- 
physiologic testing 
or 
- Long QT syndrome 
Life-threatening ventricular tachyarrhythmias and an- 
tiarrhythmic drug therapy failure 
Contraindications 
Uncontrolled congestive heart failure 
Frequent recurrences of ventricular tachycardia (eg, 1 
or more episodes daily) such that the AICD battery 
would rapidly deplete 
Data from Gabry et al,” Cannom et al,” Winkle et al,” 
Fisher et al,” Mirowski et al,” Reid et al,” and Platia et al.*’ 
of ventricular tachycardia and the rates and 
forms of ventricular tachycardia; they will also 
have undergone electrophysiologically guided 
drug therapy. Those able to exercise should be 
given an exercise-treadmill test preoperatively or 
just before hospital discharge to assess the need 
for postoperative @-blockade to prevent the heart 
rate from reaching a rate that may trigger the 
AICD.13*15 Other investigators, in addition, rec- 
ommend Holter monitoring before surgery.13,*’ 
Also, it should be known if any intravenous drugs 
were effective in suppressing the dysrhythmia. 
Indications for other preoperative tests are the 
same as with any other major thoracic procedure. 
Pr.eoperative pulmonary function tests may be 
useful to rule out chronic obstructive pulmonary 
disease or interstitial lung disease secondary to 
amiodarone toxicity. 
Patients should be on a stable antiarrhyth- 
mic drug regimen at the time of implantation if 
treating the patient with long-term antiarrhyth- 
mics is planned. Antiarrhythmic drugs may alter 
the defibrillation threshold tested intraopera- 
tively. ** Not administering the antiarrhythmic 
drug preoperatively may lead to device failure 
because the defibrillation threshold can be in- 
creased postoperatively when the antiarrhythmic 
therapy is reinstituted.** However, some prefer to 
discontinue antiarrhythmic drugs 4 to 5 half- 
lives before surgery so that dysrhythmia induc- 
tion may be made easier.23 If the patient is 
receiving amiodarone preoperatively and will not 
be postoperatively, the drug should be discontin- 
ued at least 1 month beforesurgery.” 
There is a high incidence of congestive 
heart failure among these patients. This requires 
the best possible medical control preoperatively. 
Likewise, any concurrent medical conditions re- 
quire optimal management. The patients for 
AICD have been characterized by a number of 
investigators. Table 2 lists a typical subset of 
patients for AICD implantation.24 
ANESTHESIA 
The AICD patient must be continuously 
monitored by ECG even during transport to the 
operating room. An external cardioverter-defibril- 
lator should be readily available. If the patient 
has sustained ventricular tachycardia that is 
hemodynamically stable, a precordial thump may 
be attempted and then, if unsuccessful, the pa- 
tient should be sedated and externally cardio- 
verted by synchronous cardioversion starting at 
50 J, or, at the energy level that was successful in 
the electrophysiology lab. The energy require- 
ments should then be increased to 100,200, 300, 
and 360 J. If the patient has sustained ventricu- 
lar fibrillation or ventricular tachycardia that is 
Table 2. Profile of 70 AICD Patients 
Cardiac Disease 
Coronary artery disease 
Hypertrophic cardiomyopathy 
Mitral valve prolapse 
Other valve disease 
Long QT syndrome 
Myasthenia gravis 









Ventricular tachycardia and ventricular 
fibrillation 
Preoperative 
Mean dysrhythmic episodes 
.‘No. of cardiac arrests 








2.2 f 0.9 
2.6 f 0.7 





3.3 * 2.4 
1.9 * 1.8 
4.0 * 2.3 
Abbreviations: NYHA, New York Heart Association; Cl, 
cardiac index; EF, ejection fraction; LVEDP, left ventricular 
end-diastolic pressure. 
Data from Echt and Winkle.24 
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hemodynamically unstable, then a precordial 
thump may be tried initially. If that is unsuccess- 
ful, immediate defibrillation with the energy 
level that was successful in the electrophysiologic 
laboratory or, if unknown, with 200 J, should be 
attempted and then increased to 300 and 360 J.25 
General anesthesia is required for AICD 
placement because the cardiac apex is exposed 
for patch-electrode placement. Routine moni- 
tors, including a five-lead ECG, should be used 
for anesthesia administration. In addition, these 
patients need an arterial catheter for beat-to- 
beat pressure monitoring. Patients for AICD 
implantation commonly have a central venous 
catheter inserted. At most centers, a pulmonary 
artery catheter is used for those patients with 
markedly depressed cardiac function, severe coro- 
nary artery disease, or severe pulmonary hyper- 
tension.15*23 Others, however, use a pulmonary 
artery catheter as part of their routine manage- 
ment.13 These monitors are usually inserted be- 
fore anesthetic induction. Some report using 
procaine instead of lidocaine for local anesthesia 
because lidocaine may interfere with the induc- 
tion of the ventricular dysrhythmia.23 
Anesthetic management is based on the 
patient’s underlying disease and pathophysio- 
logic status and whether or not other cardiac 
surgery is being performed. The implantation of 
an AICD presents a number of challenges to the 
anesthesiologist. There are high incidences of 
ischemic heart disease and depressed cardiac 
function in patients undergoing AICD implanta- 
tion. Despite this, patients can be managed with 
the expectation of extubating them on the operat- 
ing room table or in the immediate postoperative 
period. 
Intraoperatively, a number of tests must be 
performed. Each individual lead as well as the 
entire AICD system must be tested. Continuity 
of the lead system needs to be ensured. Also, 
proper lead positioning needs to be checked SO 
that the amplitude of the signals is within accept- 
able limits. The electrode position of the rate- 
sensing lead should be placed so that the largest 
ventricular electrogram is obtained. The signal 
should be no less than 4 mV. This increases the 
chance of adequate signal detection during ven- 
tricular tachycardia. If a spring-patch electrode 
is used, it should be positioned at the junction of 
the superior vena cava and right atrium. The 
signal from the patch electrode is also recorded. 
A signal of less than 5 mV implies that the 
electrode is over previously infarcted myocar- 
dium or is making poor contact with the ventri- 
cle. 
The energy required to convert the pa- 
tient’s malignant dysrhythmia needs to be deter- 
mined. Intraoperatively, the patient’s malignant 
rhythm is induced by programmed ventricular 
stimulation or alternating current. In spite of a 
history of recurrent dysrhythmias and ability to 
induce these dysrhythmias while awake, they are 
sometimes difficult to induce under anesthesia. 
Ventricular tachycardia may not be inducible in 
as many as 10% to 40% of patients undergoing 
dysrhythmia surgery who are under anesthe- 
sia. 26-28 Multiple attempts at dysrhythmia induc- 
tion are sometimes necessary. In addition, isopro- 
terenol or epinephrine is sometimes required to 
facilitate dysrhythmia induction. Some electro- 
physiologists use alternating current for the induc- 
tion of ventricular fibrillation.29 The defibrilla- 
tion thresholds for both ventricular tachycardia 
and fibrillation need to be determined when the 
patient’s underlying dysrhythmia is ventricular 
tachycardia, because ventricular tachycardia may 
degenerate into ventricular fibrillation before or 
after cardioversion. The defibrillation threshold 
is determined by using an external cardioverter- 
defibrillator attached to the defibrillation leads of 
the AICD. At least a 10-J margin above the 
energy required to defibrillate the heart is consid- 
ered optimal for the energy to be delivered by the 
AICD.” If a defibrillation threshold less than or 
equal to 15 J is not achieved with the initial lead 
position, different lead configurations are tested 
until an adequate threshold is identified. A thresh- 
old of less than 25 J is necessary for AICD 
implantation.i3 Between four and eight cardiover- 
sions and defibrillations are fairly typical. As 
many as 20 to 30 dysrhythmia inductions and 
countershocks are possible without apparent ill 
effect to the patient.16 Intraoperative testing of 
the lead configuration is thought to improve 
results because, in one series, 12% of the patients 
would have had inadequate dysrhythmia termina- 
tion in the initial configuration.16 Arterial pres- 
sure needs to be monitored continuously during 
dysrhythmia inductions. Blood pressure should 
be allowed to return to the baseline level between 
inductions. If hypotension persists, inotropic sup- 
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port should be instituted and the number of 
dysrhythmia inductions kept to a minimum. A 
minority of patients may exhibit prolonged pauses 
and severe bradycardia after each shock. These 
patients may require insertion of a separate, 
standby ventricular pacemaker.30 
DRUG INTERACTIONS 
Volatile anesthetics suppress the induction 
of ventricular tachycardia by programmed elec- 
trical stimulation in the canine mode1.31932 How- 
ever, a narcotic-based technique has been shown 
to have minimal effects on the induction of 
ventricular tachycardia.31 The effects of anesthet- 
ics commonly used for AICD implantation on 
defibrillation thresholds are largely unknown. 
Chloralose and pentobarbital have been reported 
to have no significant effect.33*34 Furthermore, 
there may be significant interactions between 
anesthetics and antiarrhythmics on the defibrilla- 
tion threshold. Lidocaine has produced signifi- 
cant, dose-dependent increases in transthoracic 
and internal defibrillation thresholds in pentobar- 
bital-anesthetized dogs. However, in chloralose- 
anesthetized dogs, no significant changes were 
noted with similar lidocaine concentrations.33Y35 
Animal and clinical studies suggest that 
therapeutic levels of some Vaughan-Williams 
class-IB and -1C drugs may increase the defibril- 
lation threshold. The effects of class-IA drugs 
may manifest themselves only at toxic doses.** 
(See Table 3 for a subclassification of class-I 
antiarrhythmic agents). High doses of quinidine, 
a class-IA drug, have been reported to cause 
large increases in the transthoracic defibrillation 
threshold.37 Other investigators have found small 
or no increases in internal defibrillation thresh- 
o1d.38*3g Flecainide, a class-IC drug, causes a 
marked increase in defibrillation threshold.@ 
Therapeutic doses of propranolol, a class-II agent, 
Table 3. Subclassification of Class-l 
Antidysrhythmic Agents 















Modified and reproduced with permission from Mecha- 
nisms and Treatment of Cardiac Arrhythmias by Joseph Reiser, 
1984, Urban & Schwartzenberg, Baltimore-Munich. 
do not alter defibrillation energy requirements.38 
At high doses of propranolol, the internal defibril- 
lation threshold was increased. This is perhaps a 
result of the membrane-stabilizing effect of high- 
dose propranolol!’ Amiodarone, a class-III agent, 
has been reported to cause a marked increase in 
the defibrillation threshold.13942 
Patients undergoing AICD implantation 
frequently need concomitant drug therapy. 
Present devices have a maximum energy output 
of approximately 30 to 32 J. The safety margin of 
defibrillation may be inadequate when drugs 
affecting the electrophysiological characteristics 
of the diseased myocardium are used. Some 
authorities recommend testing the efficacy of the 
AICD in the electrophysiologic laboratory 
when a drug regimen is changed after AICD 
implantation.** 
The work presented has many theoretical 
implications for anesthesiologists. In a patient 
with an AICD in situ, it is important to be 
prepared for AICD failure during anesthesia 
because anesthetics or adjuncts to anesthesia 
could alter defibrillation thresholds. Also, if cer- 
tain anesthetics lower the defibrillation thresh- 
old, then patients receiving these anesthetics at 
the time of AICD implantation would have 
artificially low threshold measurements, which 
might put them at risk for subsequent AICD 
failure. Conversely, if certain anesthetics raise 
the defibrillation threshold, during AICD implan- 
tation they may subject the patient to unneces- 
sary attempts to find a more optimal lead config- 
uration. In practice, there have been no reported 
cases of adverse anesthetic interactions. 
SURGICAL CONSIDERATIONS 
There are a number of different surgical 
approaches used for AICD implantation. If a 
superior vena caval spring lead or the endocar- 
dial rate-detection lead are used, they can be 
inserted percutaneously through the subclavian 
vein under local anesthesia before going to the 
operating room, thereby saving time and the 
need for fluoroscopy once there. Later, under 
general anesthesia, the leads are tunnelled subcu- 
taneously to the pulse generator in the abdomen. 
When either type of lead system inserted from 
the subclavian vein is used, avoidance of intracar- 
diac monitoring catheters is recommended. 
The surgical approaches available for AICD 
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implantation include subxiphoid thoracotomy, 
median sternotomy, left anterior thoracotomy, 
and left subcostal thoracotomy in the supine 
position. The underlying cardiac disease, the 
presence of a previous cardiac surgical proce- 
dure, and the need for myocardial revasculariza- 
tion or endocardial resection determine the ap- 
proach to be used. The subxiphoid approach is 
the least traumatic, and operative times are 
shorter with it. The incision is limited, so postop- 
erative pain is minimal. It is particularly useful 
for patients with end-stage cardiac disease. How- 
ever, it requires a pericardium free of surgical 
scarring. The median sternotomy is the approach 
of choice for those patients also undergoing 
open-heart procedures. In addition, it provides 
the widest cardiac exposure, which is particularly 
useful when all the leads are epicardial.28 In 
patients with a previous median sternotomy, the 
left anterior thoracotomy is a commonly used 
alternative.43 It avoids scar tissue associated with 
previous cardiac surgery. The left subcostal tho- 
racotomy has been used by some surgeons be- 
cause it is thought to minimize postoperative 
pain.44 
POSTOPERATIVE CONSIDERATIONS 
In the immediate postoperative period, 
AICD patients are susceptible to transient su- 
praventricular and ventricular dysrhythmias. Be- 
cause these dysrhythmias may trigger unneces- 
sary shocks, the device is turned off in the initial 
postoperative period, and the patient must be 
carefully monitored and treated for sustained 
dysrhythmias. An increased incidence of postop- 
erative ventricular tachycardia has been noted in 
patients with epicardial rate-counting leads, and 
atria1 dysrhythmias may be more common in 
those with the patch-patch defibrillation elec- 
trode configuration. l3 Thus, transthoracic car- 
diac defibrillators should be readily available 
until the unit is activated. External cardioversion 
has been used successfully without damage to the 
AICD.” The paddles of the external defibrillator 
should be placed perpendicular to the line be- 
tween the two implanted defibrillating electrodes 
in order that the energy pass directly to the 
myocardium. Adhesive external defibrillation 
pads, which can be left on the patient while the 
device is deactivated, allow for ready cardiover- 
sion and defibrillation in the proper paddle orien- 
tation. The AICD device is activated when the 
patient is more stable and ready to be transferred 
to an unmonitored area.20*24 
During the implantation of the AICD de- 
vice, patients undergo multiple dysrhythmia in- 
ductions. These are associated with periods of 
low or no blood pressure. It can be expected that 
the myocardium will be “stunned” postopera- 
tively. Two-dimensional echocardiography was 
performed in a series of six patients undergoing 
AICD implantation. The mean ejection fraction 
before the first induced ventricular dysrhythmia 
was 28% + 1.4% versus 27% f 1.9% after a mean 
of six ventricular tachycardia/fibrillation epi- 
sodes. The investigators concluded that electro- 
physiologic testing during AICD implantation 
does not have clinically important depressant 
effects on left ventricular ejection fraction.45 
At some centers, all patients undergo test- 
ing of the device in the electrophysiologic labora- 
tory before discharge. Proper sensing and termi- 
nation of ventricular tachycardia and fibrillation 
must be found.13 After discharge, patients are 
followed up at 2-month intervals for battery 
checks. Magnet tests provide a digital readout of 
the number of shocks delivered and the capacitor 
charge time. Longevity of the current devices is 
less than ideal; most units require changes within 
24 months.46 Under sterile conditions in the 
electrophysiology laboratory, the pulse generator 
may be replaced under local anesthesia. Yearly 
chest radiographs should be obtained to check for 
lead migration or fracture. 
COMPLICATIONS 
The surgical complications from one recent 
study13 are shown in Table 4. The most common 
Table 4. Postoperative Complications in 94 Patients 
Pulmonary complications 
Postoperative ventricular tachycardia 



















Modified and reprinted with permission from the Ameri- 
can College of Cardiology (Journal of the American College of 
Cardiology, vol 11, 1988, pp 1278-l 286). 
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problems were pulmonary, comprising hypox- 
emia, pneumonia, left lower lobe collapse, pneu- 
mothorax, and pleural effusions. They occurred 
more frequently in patients who had undergone a 
left anterior thoracotomy. The majority of these 
complications resolved with chest physiotherapy. 
Later complications included lead migra- 
tion, lead fracture, pacemaker-AICD interac- 
tions, and unnecessary shocks.” To minimize 
unnecessary shocks, treadmill exercise testing 
should be performed to assess maximal -heart 
rate. P-blockade should then be instituted if 
necessary. 
Inappropriate AICD discharges caused by 
sensing of noncardiac myopotentials have been 
reported.” By applying a magnet to the AICD, 
this condition can be diagnosed. Rapid erratic 
tones that are not synchronous with the QRS 
complex and are emitted from the piezoelectric 
crystal when the patient exercises are indicative 
of this problem.47 
Patients with pacemakers present special 
problems for proper AICD function. The pace- 
maker and AICD may interact in a number of 
unfavorable ways. During a tachydysrhythmia, 
the pacer may not sense the ventricular tachycar- 
dia or fibrillation and continue to fire at the 
programmed pacing rate. The AICD may then 
ignore the tachydysrhythmia in favor of the 
regular pacing spikes of the pacemaker and, as a 
result, not fire. Conversely, inappropriate AICD 
discharge may occur if the AICD double-counts 
both the pacing spike and the evoked ventricular 
depolarization. These problems are more com- 
mon with a unipolar pacemaker because of the 
larger magnitude of the pacemaker stimulus 
artifact.48 Only bipolar pacemakers should be 
used in conjunction with an AICD. 
MANAGEMENT OF PATIENTS WITH AN 
AUTOMATIC INTERNAL 
CARDIOVERTER-DEFIBRILLATOR 
There has not been a great deal of experi- 
ence with anesthesia for patients with an AICD 
in situ. The anesthetic technique should be the 
same that normally would be used for the given 
procedure and the given pathophysiological state 
of the patient. Some suggest a digital plethysmo- 
graph as an alternative to an arterial catheter to 
indicate the presence of pulsatile flow.23 Monitor- 
ing should be guided by the patient’s underlying 
disease and by the surgical procedure. Use of 
gloves has been advocated because the AICD 
may discharge at any time and especially during 
cardiopulmonary resuscitation.49 
Electromagnetic interference can cause in- 
appropriate AICD inhibition or discharge. Elec- 
trocautery is a source of interference that is of 
particular concern to the anesthesiologist. It is 
generally recommended that electrocautery be 
used only when the pulse generator is deac- 
tivated.15 Gaba et a123 report a patient having a 
countershock sequence initiated by electrocau- 
tery and precipitating ventricular tachycardia in 
the vicinity of the generator during surgery. 
Moreover, use of electocautery in proximity to 
the AICD can cause direct thermal injury to the 
device, electrode leads, or electrode-myocardial 
interface. However, the AICD has been designed 
to resist interference from outside electromag- 
netic sources, and some think electrocautery can 
be used with caution while the AICD is ac- 
tivated.23 If electrocautery is used when the 
AICD is activated, the electrocautery ground 
pad should be placed on the patient so that the 
axis of the ground pad and the surgical site is 
oriented perpendicular to the axis of the bipolar 
rate-sensing leads. In addition, the electrocau- 
tery unit should be used only in short bursts 
because the AICD requires 5 to 20 seconds to 
sense a dysrhythmia. Moreover, a ring magnet 
must be immediately available to deactivate the 
AICD device. Whether the AICD is deactivated 
or activated, an external cardioverter-defibril- 
lator must also be readily available. Nuclear 
magnetic resonance scanners and shock-wave 
lithotripsy are other causes of electromagnetic 
interference important to the anesthesiologist. 
Patients with AICD devices should not enter the 
vicinity of a nuclear magnetic resonance scanner, 
and patients for lithotripsy should have their 
devices deactivated before treatment. 
The pathological effects of the AICD and 
of multiple internal defibrillations have been 
examined at autopsy in 25 patients. It was found 
that pericarditis is a universal finding of little 
clinical significance. The presence of the superior 
vena caval lead was associated with thrombi in 
17% of the patients. However, no patient in the 
series died of pulmonary embolism. Multiple 
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defibrillations led to localized myocardial pathol- 
ogy adjacent to the patch electrode. It was 
concluded that multiple defibrillations by the 
AICD cause inconsequential myocardial and 
pericardial injury.” In addition, global and re- 
gional left ventricular function have been fol- 
lowed via M-mode echocardiography in 15 pa- 
tients undergoing AICD implantation. The 
patients were studied preoperatively and then 
followed for a period of approximately 6 months 
after AICD implantation. The investigators in- 
ferred that AICD implantation did not signifi- 
cantly alter ventricular function.51 
FUTURE 
A number of improvements will be in- 
cluded in devices of the future. A programmable 
AICD device was recently released for clinical 
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use that has low-energy cardioversion capabili- 
ties, flexible settings for the heart rate which will 
trigger a countershock, and a choice of including 
the PDF in the countershock algorithm. Other 
advances will include backup bradycardia pac- 
ing, incorporation of hemodynamic sensors into 
the device, and antitachycardia pacing. Over- 
drive pacing can effectively terminate ventricular 
tachycardia.j2 By combined use of an antitachy- 
cardic pacemaker and AICD, the number of 
discharges from the AICD can be reduced. This 
would improve patient comfort and improve 
battery longevity. 53 In addition, the epicardial 
patch defibrillator may be replaced by a subcuta- 
neous patch defibrillator, thereby simplifying the 
surgical procedure and perhaps decreasing the 
rate of morbidity. 
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